Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 21, 2007; 13(23): 3164-3170
Published online Jun 21, 2007. doi: 10.3748/wjg.v13.i23.3164
Published online Jun 21, 2007. doi: 10.3748/wjg.v13.i23.3164
SSTR-negative group | Control group | Octreotide group | P | |||
Number of patients | 66 | 30 | 30 | df | P | |
Age (yr) | 69.4 ± 5.6 | 69.5 ± 5.6 | 69.4 ± 6.3 | F = 0.009 | 125 | > 0.05 |
Sex | ||||||
Male | 36 (55%) | 22 (73%) | 20 (67%) | χ2 = 3.45 | 2 | > 0.05 |
Etiology | χ2 = 9.133 | 4 | > 0.05 | |||
HBV | 38 (58%) | 10 (33%) | 10 (33%) | |||
HCV | 26 (39%) | 17 (57%) | 19 (63%) | |||
HBV + HVC | 2 (3%) | 3 (10%) | 1 (3%) | |||
Morphology | χ2 = 0.842 | 4 | > 0.05 | |||
Multi nodular | 13 (20%) | 6 (20%) | 7 (23%) | |||
Massive | 45 (68%) | 20 (67%) | 21 (70%) | |||
Diffuse | 8 (12%) | 4 (13%) | 2 (7%) | |||
AFP | 3208 ± 4500 | 3096 ± 4500 | 2714 ± 5049 | F = 0.057 | 125 | > 0.05 |
Metastases | 8 (12%) | 7 (23%) | 4 (13%) | χ2 = 2.118 | 2 | > 0.05 |
Cirrhosis | ||||||
Stage B | 32 (49%) | 19 (63%) | 15 (50%) | χ2 = 1.91 | 2 | > 0.05 |
BCLC | ||||||
Stage C | 56 (85%) | 25 (83%) | 25 (83%) | χ2 = 0.054 | 2 | > 0.05 |
- Citation: Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial. World J Gastroenterol 2007; 13(23): 3164-3170
- URL: https://www.wjgnet.com/1007-9327/full/v13/i23/3164.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i23.3164